New Genmab cancer treatment could launch in matter of weeks

Genmab is all set for the FDA’s decision on epcoritamab, slated for arrival during next week.

by marketwire, translated by christian radich hoffman & katrine gøthler

Genmab has its hopes up for an approval of prospective cancer treatment epcoritamab in the US falling during next week, and the company is ready to commence a rapid market launch.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

Access all locked articles
Receive our daily newsletters
Access our app

Get full access for you and your coworkers

Start a free company trial today

Genmab-developed drug reaches first-quarter expectations in US
For subscribers
Genmab adds 35% to revenue – bottom line drops below guidance
For subscribers
Genmab's costs increased in 2022 – trend to continue in 2023
For subscribers

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Pharma & biotech

Investment bank: Novo Nordisk's patent victory is a small victory as price negotiations loom

The market’s attention is more focused on public health insurance Medicare’s new price negotiations under the so-called Inflation Reduction Act.

For subscribers

Pharma & biotech

FDA approves Novo Nordisk drug to treat rare condition

For subscribers

Fujifilm Diosynth Biotechnologies' factory in Hillerød, Denmark. | Foto: Liselotte Plenov / Fotorummet / Pr

Pharma & biotech

Fujifilm expands management with former Leo executive

For subscribers

Foto: Andrew Kelly/Reuters/Ritzau Scanpix

Pharma & biotech

Low share price may knock Galecto off the stock exchange

For subscribers

Pharma & biotech

Snack maker keeps an eye on Novo Nordisk's obesity drug

Foto: Yuriko Nakao/Reuters/Ritzau Scanpix

Medtech

Olympus appoints new chief medical officer

For subscribers

Novo Nordisk's semaglutide to be studied for positive effect on alcoholics
Previous studies have shown that alcohol cravings disappeared when people were treated with GLP-1 agonist exanatide.
For subscribers
Vaccine breakthrough behind mRNA shots wins Nobel Prize
The two scientists will share the 11 million-krona ( USD 1 million) award, the Nobel Assembly at the Karolinska Institutet in Stockholm said in a statement Monday.
For subscribers
WS Audiology hires new chief technology officer from car manufacturer
He succeeds chief research & development officer Stefan Menzl, who is stepping down after six years.
For subscribers
Novo Nordisk files lawsuit against US authorities ahead of price negotiation
The litigation is the latest in a long line of industry lawsuits related to price negotiations.
For subscribers
FDA rejects atopic dermatitis drug lebrikizumab
Eli Lilly had expected a launch this year.
For subscribers
FDA updates Novo Nordisk's Ozempic drug label with side effect alert
The diabetes drug might cause a potentially fatal intestinal blockage, the authorities warn.
For subscribers

FDA approves Novo Nordisk drug to treat rare condition

The marketing authorization applies to children and adolescents aged 9 years and older, as well as adults with ”relatively” preserved kidney functions.

For subscribers

Pharma & biotech

Fujifilm expands management with former Leo executive

The contract manufacturer has hired a chief people officer with immediate effect.

For subscribers

Pharma & biotech

Snack maker keeps an eye on Novo Nordisk's obesity drug

”As with anything that could potentially impact our business, we’re looking at it,” says the former Kellogg’s CEO.

Genmab CEO Jan van de Winkel and director general of The Confederation of Danish Industry, Lars Sandahl Sørensen. | Photo: Genmab / PR

Pharma & biotech

Genmab has officially opened its new headquarters

The CEO describes the new premises as a symbol of the company’s commitment to advancing science and innovation.

For subscribers

The approval in Japan is based on two phase I/II studies with Epkinly. | Foto: Uncredited/AP/Ritzau Scanpix

Pharma & biotech

Japanese authorities approve cancer drug by Genmab and Abbvie

The drug was launched in the US at the end of the second quarter and has also received a positive recommendation from the regulatory authorities in Europe.

For subscribers

The EMA advisory panel, CHMP, recommends approving drug candidate lebrikizumab in Europe, which is marketed by Spanish dermatology company Almirall under the trade name, Ebglyss. | Foto: Mikkel Aabenhus Hemmingsen / Medwatch

Pharma & biotech

EMA committee recommends Almirall's psoriasis drug

The path is now cleared for Spanish Almirall to sell and market its candidate, lebrikizumab, in Europe for the treatment of adolescents and adults with moderate-to-severe atopic dermatitis.

For subscribers